Stryker Corporation $SYK Shares Purchased by Noesis Capital Mangement Corp

Noesis Capital Mangement Corp raised its position in Stryker Corporation (NYSE:SYK) by 3.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,303 shares of the medical technology company’s stock after acquiring an additional 2,394 shares during the quarter. Stryker makes up about 3.5% of Noesis Capital Mangement Corp’s investment portfolio, making the stock its 6th largest holding. Noesis Capital Mangement Corp’s holdings in Stryker were worth $24,358,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. United Financial Planning Group LLC acquired a new stake in Stryker in the third quarter valued at $27,000. Strive Asset Management LLC acquired a new stake in Stryker in the third quarter valued at $30,000. CGC Financial Services LLC acquired a new stake in Stryker in the fourth quarter valued at $29,000. ANTIPODES PARTNERS Ltd acquired a new stake in Stryker in the third quarter valued at $34,000. Finally, Copia Wealth Management lifted its stake in Stryker by 181.6% in the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after acquiring an additional 69 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Canaccord Genuity Group cut their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Evercore set a $355.00 price objective on shares of Stryker in a research report on Friday, May 1st. Citigroup dropped their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Finally, Barclays dropped their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $395.48.

Stryker Price Performance

Shares of SYK opened at $306.74 on Friday. The firm has a market capitalization of $117.59 billion, a PE ratio of 35.50, a PEG ratio of 1.93 and a beta of 0.80. The company’s 50-day moving average is $329.68 and its 200-day moving average is $351.73. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the prior year, the business posted $2.84 earnings per share. Stryker’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.